SRTA
SRTA
Strata Critical Medical, Inc.Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $49.3M ▼ | $17.24M ▼ | $57.42M ▲ | 116.47% ▲ | $-0.04 ▲ | $-9.24M ▼ |
| Q2-2025 | $70.8M ▲ | $22.69M ▲ | $-3.74M ▼ | -5.29% ▲ | $-0.05 ▼ | $-3.18M ▲ |
| Q1-2025 | $54.31M ▼ | $19.56M ▼ | $-3.49M ▲ | -6.43% ▲ | $-0.04 ▲ | $-5.89M ▲ |
| Q4-2024 | $54.36M ▼ | $20.96M ▼ | $-9.79M ▼ | -18.02% ▼ | $-0.12 ▼ | $-6.84M ▼ |
| Q3-2024 | $74.88M | $23.37M | $-1.95M | -2.61% | $-0.03 | $-2.26M |
What's going well?
The company reported a large net profit thanks to gains from discontinued operations and a big tax benefit. No interest expense means no debt pressure.
What's concerning?
Sales dropped sharply, margins are getting squeezed, and the core business is losing money. The profit is not from normal operations, so the underlying business remains weak.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $75.92M ▼ | $335.08M ▲ | $52.08M ▲ | $283M ▲ |
| Q2-2025 | $113.42M ▼ | $257.92M ▲ | $34.82M ▲ | $223.1M ▲ |
| Q1-2025 | $120.01M ▼ | $250.55M ▼ | $30.82M ▼ | $219.73M ▼ |
| Q4-2024 | $127.14M ▼ | $256.68M ▼ | $34.74M ▼ | $221.94M ▼ |
| Q3-2024 | $136.34M | $282.94M | $49.45M | $233.5M |
What's financially strong about this company?
SRTA has very low debt, lots of equity, and more than enough current assets to pay its bills. The company paid down debt and grew its book value sharply this quarter.
What are the financial risks or weaknesses?
Cash and investments dropped by a third, and a big jump in goodwill means more risk if acquisitions don't work out. Receivables and payables both rose fast, which could squeeze cash flow if not managed.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-9.66M ▼ | $-31.84M ▼ | $2.4M ▼ | $-7.24M ▼ | $-37.3M ▼ | $-34.97M ▼ |
| Q2-2025 | $-3.74M ▼ | $-4.21M ▲ | $28.68M ▲ | $14K ▼ | $24.63M ▲ | $-6.94M ▲ |
| Q1-2025 | $-3.49M ▲ | $-4.55M ▼ | $20.41M ▲ | $60K ▲ | $16.04M ▲ | $-7.7M ▼ |
| Q4-2024 | $-9.79M ▼ | $13K ▼ | $3.98M ▲ | $-5.64M ▼ | $-1.76M ▲ | $-5.03M ▼ |
| Q3-2024 | $-1.95M | $6.36M | $-12.65M | $-731K | $-6.96M | $-3.56M |
What's strong about this company's cash flow?
Working capital changes provided a temporary boost to cash flow, and the company is not taking on new debt or diluting shareholders much. If the business can cut cash burn or grow revenue quickly, there's a chance to stabilize.
What are the cash flow concerns?
Cash burn jumped sharply this quarter, with $35 million in free cash flow lost and only $23 million left in the bank. Without a turnaround, the company will need to raise money soon or risk running out of cash.
Revenue by Products
| Product | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
Medical Segment | $40.00M ▲ | $40.00M ▲ | $40.00M ▲ | $50.00M ▲ |
Passenger Segment | $40.00M ▲ | $20.00M ▼ | $20.00M ▲ | $30.00M ▲ |
Revenue by Geography
| Region | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
NonUS | $10.00M ▲ | $0 ▼ | $10.00M ▲ | $10.00M ▲ |
UNITED STATES | $60.00M ▲ | $50.00M ▼ | $50.00M ▲ | $60.00M ▲ |
Q3 2025 Earnings Call Summary
Read Call Summary5-Year Trend Analysis
A comprehensive look at Strata Critical Medical, Inc.'s financial evolution and strategic trajectory over the past five years.
SRTA’s key strengths are its strong revenue growth, improving gross and operating margins, and conservative balance sheet. The company has demonstrated that it can scale sales quickly while gradually tightening its cost structure. High liquidity and low leverage provide a cushion against setbacks and give management flexibility to keep investing in growth. Rising gross profit and better operating leverage point to a business model that becomes more efficient as it grows.
The main risks center on persistent unprofitability and cash burn. Despite revenue gains and margin improvement, the company still posts sizable operating and net losses, which have accumulated into a large negative retained earnings balance. Free cash flow is consistently negative, recently exacerbated by a surge in capital expenditures. Asset and equity levels have been drifting down from prior peaks, and cash balances are shrinking, which, if continued, could eventually constrain the company’s ability to fund operations and growth without new capital.
Looking ahead, the trajectory is mixed but somewhat constructive. Operational trends—stronger revenue, better margins, and some narrowing of losses—suggest the business is moving toward a more sustainable model, especially if cost discipline continues. At the same time, the ongoing need for cash, increasing capital intensity, and lack of clear visibility into the competitive and innovation landscape introduce meaningful uncertainty. The company’s ample liquidity and low debt buy it time, but the medium‑term outlook will depend on whether it can convert growth and investment into durable, self‑funding profitability.
About Strata Critical Medical, Inc.
http://www.stratacritical.comStrata Critical Medical, Inc. provides time critical logistics solutions and specialized medical services to healthcare providers across the United States. The company operates as both an air and ground transporter of human organs for transplant. The company was formerly known as Blade Air Mobility, Inc. and change its name to Strata Critical Medical, Inc. in August 2025.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $49.3M ▼ | $17.24M ▼ | $57.42M ▲ | 116.47% ▲ | $-0.04 ▲ | $-9.24M ▼ |
| Q2-2025 | $70.8M ▲ | $22.69M ▲ | $-3.74M ▼ | -5.29% ▲ | $-0.05 ▼ | $-3.18M ▲ |
| Q1-2025 | $54.31M ▼ | $19.56M ▼ | $-3.49M ▲ | -6.43% ▲ | $-0.04 ▲ | $-5.89M ▲ |
| Q4-2024 | $54.36M ▼ | $20.96M ▼ | $-9.79M ▼ | -18.02% ▼ | $-0.12 ▼ | $-6.84M ▼ |
| Q3-2024 | $74.88M | $23.37M | $-1.95M | -2.61% | $-0.03 | $-2.26M |
What's going well?
The company reported a large net profit thanks to gains from discontinued operations and a big tax benefit. No interest expense means no debt pressure.
What's concerning?
Sales dropped sharply, margins are getting squeezed, and the core business is losing money. The profit is not from normal operations, so the underlying business remains weak.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $75.92M ▼ | $335.08M ▲ | $52.08M ▲ | $283M ▲ |
| Q2-2025 | $113.42M ▼ | $257.92M ▲ | $34.82M ▲ | $223.1M ▲ |
| Q1-2025 | $120.01M ▼ | $250.55M ▼ | $30.82M ▼ | $219.73M ▼ |
| Q4-2024 | $127.14M ▼ | $256.68M ▼ | $34.74M ▼ | $221.94M ▼ |
| Q3-2024 | $136.34M | $282.94M | $49.45M | $233.5M |
What's financially strong about this company?
SRTA has very low debt, lots of equity, and more than enough current assets to pay its bills. The company paid down debt and grew its book value sharply this quarter.
What are the financial risks or weaknesses?
Cash and investments dropped by a third, and a big jump in goodwill means more risk if acquisitions don't work out. Receivables and payables both rose fast, which could squeeze cash flow if not managed.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-9.66M ▼ | $-31.84M ▼ | $2.4M ▼ | $-7.24M ▼ | $-37.3M ▼ | $-34.97M ▼ |
| Q2-2025 | $-3.74M ▼ | $-4.21M ▲ | $28.68M ▲ | $14K ▼ | $24.63M ▲ | $-6.94M ▲ |
| Q1-2025 | $-3.49M ▲ | $-4.55M ▼ | $20.41M ▲ | $60K ▲ | $16.04M ▲ | $-7.7M ▼ |
| Q4-2024 | $-9.79M ▼ | $13K ▼ | $3.98M ▲ | $-5.64M ▼ | $-1.76M ▲ | $-5.03M ▼ |
| Q3-2024 | $-1.95M | $6.36M | $-12.65M | $-731K | $-6.96M | $-3.56M |
What's strong about this company's cash flow?
Working capital changes provided a temporary boost to cash flow, and the company is not taking on new debt or diluting shareholders much. If the business can cut cash burn or grow revenue quickly, there's a chance to stabilize.
What are the cash flow concerns?
Cash burn jumped sharply this quarter, with $35 million in free cash flow lost and only $23 million left in the bank. Without a turnaround, the company will need to raise money soon or risk running out of cash.
Revenue by Products
| Product | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
Medical Segment | $40.00M ▲ | $40.00M ▲ | $40.00M ▲ | $50.00M ▲ |
Passenger Segment | $40.00M ▲ | $20.00M ▼ | $20.00M ▲ | $30.00M ▲ |
Revenue by Geography
| Region | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
NonUS | $10.00M ▲ | $0 ▼ | $10.00M ▲ | $10.00M ▲ |
UNITED STATES | $60.00M ▲ | $50.00M ▼ | $50.00M ▲ | $60.00M ▲ |
Q3 2025 Earnings Call Summary
Read Call Summary5-Year Trend Analysis
A comprehensive look at Strata Critical Medical, Inc.'s financial evolution and strategic trajectory over the past five years.
SRTA’s key strengths are its strong revenue growth, improving gross and operating margins, and conservative balance sheet. The company has demonstrated that it can scale sales quickly while gradually tightening its cost structure. High liquidity and low leverage provide a cushion against setbacks and give management flexibility to keep investing in growth. Rising gross profit and better operating leverage point to a business model that becomes more efficient as it grows.
The main risks center on persistent unprofitability and cash burn. Despite revenue gains and margin improvement, the company still posts sizable operating and net losses, which have accumulated into a large negative retained earnings balance. Free cash flow is consistently negative, recently exacerbated by a surge in capital expenditures. Asset and equity levels have been drifting down from prior peaks, and cash balances are shrinking, which, if continued, could eventually constrain the company’s ability to fund operations and growth without new capital.
Looking ahead, the trajectory is mixed but somewhat constructive. Operational trends—stronger revenue, better margins, and some narrowing of losses—suggest the business is moving toward a more sustainable model, especially if cost discipline continues. At the same time, the ongoing need for cash, increasing capital intensity, and lack of clear visibility into the competitive and innovation landscape introduce meaningful uncertainty. The company’s ample liquidity and low debt buy it time, but the medium‑term outlook will depend on whether it can convert growth and investment into durable, self‑funding profitability.

CEO
Melissa Tomkiel
Compensation Summary
(Year )
Upcoming Earnings
ETFs Holding This Stock
Summary
Showing Top 3 of 32
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1

